Fig. 4.

Effect of baseline serum IgE concentrations on annual asthma exacerbation rate reduction with benralizumab vs. placebo (full analysis set; baseline blood eosinophil counts ≥ 300 cells/µL). CI confidence interval, IgE immunoglobulin E, Q quartile, Q8W every 8 weeks (first three doses every 4 weeks). Estimates were calculated via a negative binomial model, with adjustments for study, treatment, region, prior exacerbations, and oral corticosteroid use at time of randomization. The log of each patient’s corresponding follow-up time was used as an offset variable in the model to adjust for different exposure times during which the events occurred. ^ap < 0.01